We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evaluation of artemisinins for the treatment of acute myeloid leukemia.
- Authors
Drenberg, Christina; Buaboonnam, Jassada; Orwick, Shelley; Hu, Shuiying; Li, Lie; Fan, Yiping; Shelat, Anang; Guy, R.; Rubnitz, Jeffrey; Baker, Sharyn; Drenberg, Christina D; Orwick, Shelley J; Shelat, Anang A; Guy, R Kiplin; Baker, Sharyn D
- Abstract
<bold>Purpose: </bold>Investigate antileukemic activity of artemisinins, artesunate (ART), and dihydroartemisinin (DHA), in combination with cytarabine, a key component of acute myeloid leukemia (AML) chemotherapy using in vitro and in vivo models.<bold>Methods: </bold>Using ten human AML cell lines, we conducted a high-throughput screen to identify antimalarial agents with antileukemic activity. We evaluated effects of ART and DHA on cell viability, cytotoxicity, apoptosis, lysosomal integrity, and combination effects with cytarabine in cell lines and primary patient blasts. In vivo pharmacokinetic studies and efficacy of single-agent ART or combination with cytarabine were evaluated in three xenograft models.<bold>Results: </bold>ART and DHA had the most potent activity in a panel of AML cell lines, with selectivity toward samples harboring MLL rearrangements and FLT3-ITD mutations. Combination of ART or DHA was synergistic with cytarabine. Single-dose ART (120 mg/kg) produced human equivalent exposures, but multiple dose daily administration required for in vivo efficacy was not tolerated. Combination treatment produced initial regression, but did not prolong survival in vivo.<bold>Conclusions: </bold>The pharmacology of artemisinins is problematic and should be considered in designing AML treatment strategies with currently available agents. Artemisinins with improved pharmacokinetic properties may offer therapeutic benefit in combination with conventional therapeutic strategies in AML.
- Subjects
ARTEMISININ; ACUTE myeloid leukemia treatment; CYTARABINE; CELL-mediated cytotoxicity; PHARMACOKINETICS; DRUG dosage; DRUG efficacy; THERAPEUTICS; REACTIVE oxygen species; ANIMAL experimentation; ANTIMALARIALS; ANTINEOPLASTIC agents; APOPTOSIS; CELL lines; CELL physiology; LYSOSOMES; MICE; RESEARCH funding; HIGH throughput screening (Drug development); ACUTE myeloid leukemia
- Publication
Cancer Chemotherapy & Pharmacology, 2016, Vol 77, Issue 6, p1231
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-016-3038-2